Brief: Lipidor Signs Agreement With Cro

Lipidor AB

07/07/2020 10:35

July 7 (Reuters) - Lipidor AB  LIPI.ST :
    * LIPIDOR SIGNS AGREEMENT WITH CRO FOR IMPLEMENTATION OF PHASE III CLINICAL STUDY OF DRUG
CANDIDATE AKP-02 AGAINST PSORIASIS
    * LIPIDOR AB - STUDY IS EXPECTED TO COMMENCE IN Q1 2021 WITH FINAL REPORTING IN Q1 2022.
    * LIPIDOR AB - COST OF PHASE III STUDY IS COVERED BY LIPIDOR'S EXISTING FUNDS.
    * LIPIDOR AB - DISCUSSIONS WITH CLINICAL TRIAL MATERIAL MANUFACTURERS ARE ONGOING AND AN
AGREEMENT
IS EXPECTED TO BE IN PLACE IN Q3 2020.

Source text for Eikon:  ID:nWkr96RFRj 
Further company coverage:  LIPI.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))